Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Measure the 1 year survival of non small cell lung cancer (NSCLC) patients who are being treated with pemetrexed in combination with cisplatin and radiation.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cisplatin; Pemetrexed

Criteria

Inclusion Criteria:

Some of the requirements to be in this study are:

• Patient must be at least 18 years old.

• Patient must have been diagnosed with non-small cell lung cancer.

• Patient must be able to visit the doctor's office once a week.

• Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study.

• Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug.

Exclusion Criteria:

Patients cannot participate in this study for any of the following reasons:

• Patient has previously had chemotherapy.

• Patient has previously had thoracic radiation therapy.

• Patient has received treatment within the last 30 days with a drug that has not received approval by Health Canada for any indication at the time of study entry.

• Female patient is pregnant or breast-feeding.

• Patient is unsuitable to participate in the study in the opinion of the investigator.

• Patient is unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone.